Origin of  leukemia in children with Down syndrome

Origin of  leukemia in children with Down syndrome

For the first time, the researchers have mapped out where and how leukemia begins and develops in infants with Down syndrome in preclinical models, paving the way to potentially prevent this cancer in the future.

Children with Down syndrome have a 150-fold increased risk of developing myeloid leukemia within the first five years of their life. Yet the mechanism by which the extra copy of chromosome 21 predisposes to leukemia remains unclear.

Down syndrome is a genetic disorder caused by a random error in cell division in early human development that results in an extra copy of chromosome 21. This extra copy is what causes the developmental changes and physical traits associated with the syndrome, including the predisposition to leukemia.

However, the exact blood cell type in which leukemia begins in fetal development, along with the genetic alterations that cause this cell to become preleukemic, has eluded researchers until now. Furthermore, the additional mutations that must accumulate during childhood to transform preleukemia into acute leukemia were unknown.

Using a preclinical model that includes human Down syndrome cells from a human tissue biobank, along with an enhanced CRISPR/Cas9 method for gene alteration in human blood stem cells that was developed, the team set out to chart the steps involved in this specific leukemia evolution.

Transient preleukemia is a unique condition frequently occurring in newborns with Down syndrome, which can either spontaneously disappear within days to months of birth, or transform into acute myeloid leukemia within four years by acquiring additional mutations in some individuals.

What the authors revealed in this work was the distinct cellular and genetic events related to transient preleukemia, from their beginnings in the fetus, to further progression to leukemia in childhood.

Specifically, the team was able to test a variety of blood cell types and pinpoint that transient preleukemia originates only from long-term hematopoietic stem cells (HSCs), with the GATA1 mutation, as early as the second trimester of a fetus with Down syndrome. Preleukemia does not begin in HSCs from non-Down syndrome samples.

Only HSCs are able to regenerate the entire blood system and maintain long-term output due to their unique continuous capacity for self-renewal. In a broader picture, the fact that the cellular origin of pediatric leukemia is limited to only long-term HSCs might have implications for other kinds of childhood leukemias beyond Down syndrome.

Acute leukemia happens only after the first two mutations - the extra copy of chromosome 21 and the GATA1 mutation - are in place and have "primed" the progeny or descendants downstream of the altered long-term HSCs to acquire further mutations that lead to fully transformed acute leukemia, explains the author.

The team also identified CD117/KIT as a unique protein cell surface marker on the altered disease-driving stem cells that causes the cells to proliferate. In the preclinical model and setting, the researchers were able to target and eliminate preleukemic stem cells using small molecule CD117/KIT inhibitors to prevent their progression to acute leukemia.

The researchers note that this preventative strategy could potentially be used in Down syndrome newborns and even expanded to other childhood leukemias that are known to be initiated during fetal development.

"The clinical significance of being able to target pre-cancerous lesions and preventing progression to cancer is profound," says the author, "It would transform the pediatric cancer field."